Emerald Therapeutics, a Menlo Park, California-based provider of a life sciences laboratory that scientists can remotely access via the Internet, completed a $13.5m financing.
The round was led by Founders Fund and Max Levchin, a PayPal co-founder, along with investment from Schooner Capital. Brian Singerman from Founders Fund and Max Levchin, a co-founder and former CTO at PayPal, both serve on the Board of Directors at Emerald.
Led by Dr. Brian Frezza and Dr. D.J. Kleinbaum, co-founders and co-CEOs, the company has just released its first product: the Emerald Cloud Laboratory (ECL), a state-of-the-art life sciences laboratory that scientists can remotely access via the Internet where automated robotics conduct experiments exactly as specified by the user.
Scientists can log onto a website and specify all of the parameters for a given experiment as if they were standing in front of the instrument. The experiment is then executed using Emerald’s robotically automated systems, and all of the data generated is automatically cataloged and placed into a database where it is accessible to the user.
The system also provides tools to plot, analyze, and share data with other scientists.